Circumvent Pharmaceuticals was founded with the mission to develop precision medicines for neurodegenerative diseases, addressing a significant unmet need in this area. The company focuses on heritable forms of neurodegeneration to facilitate drug discovery and development for both rare and common neurodegenerative conditions. Their initial target is Batten Disease, a rare and fatal disorder, with plans to expand their research and treatment options to other neurodegenerative diseases.
Notable affiliated individuals and investors include experts in the field of neurodegenerative research and prominent venture capital firms specializing in biotech innovations. Circumvent has achieved significant milestones in preclinical trials, showcasing promising results that have garnered attention within the scientific community. Their impact lies in pioneering new treatment pathways that could potentially alter the course of neurodegenerative diseases, offering hope to patients and families affected by these debilitating conditions.

CuraSen Therapeutics
curasen.com

Enterin
enterininc.com

NeuroGenetic Pharmaceuticals

Kurve Therapeutics
kurvetx.com

Selonterra
selonterra.com

ESCAPE Bio
escapebio.com

NeuroX1
neurox1.com

Pharmatrophix
pharmatrophix.com

Cerevance
cerevance.com

Engrail Therapeutics
engrail.com

Lysosomal Therapeutics
lysosomaltx.com

Vanqua Bio
vanquabio.com

Woolsey Pharmaceuticals
woolseypharma.com
Triplet Therapeutics
triplettx.com

Convalesce
convalesce.co

Visum Pharma
visumpharmainc.com

Neomorph
neomorph.com

Ceptur Therapeutics
cepturtx.com

Lucy Therapeutics

Cydan
cydanco.com
Circumvent's most recent funding round was for $495k (USD) in November 2021.
As of Nov 1, 2021, Circumvent has disclosed funding of $4.7M (USD).